Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Alaunos Therapeutics, Inc. (TCRT)

Alaunos completes Velaris acquisition and announces $350 million private placement

Neutral Impact 5 of 5 m&a Written later

Alaunos Therapeutics completed its merger with privately held Velaris Therapeutics on October 13, 2026, making Velaris a wholly owned subsidiary. A concurrent $350 million private placement is expected to close on October 14, 2026, and the filing says Velaris holders and the investors will receive large amounts of convertible preferred stock, which can convert into common shares and would dilute existing stockholders once converted.

Key points

  • Velaris holders received 105,286 Series B and 33,054 Series C non-voting convertible preferred shares, each convertible into 1,000 common shares, subject to conditions.
  • Private placement covers 687,789 common shares at $1.4357 per share and 243,063 Series C preferred shares at $1,435.70 per share, for an aggregate purchase price of approximately $350 million.
  • Stockholder meeting proposals include conversion approval, an authorized share increase, a name change to Velaris Therapeutics, a reverse stock split and a new equity plan; three directors are to resign upon conversion approval.

The filing

CompanyAlaunos Therapeutics, Inc. (TCRT)
Form8-K, current report
Filed with the SECOct 13, 2026, 9:28 AM ET
Accession number0001193125-26-419829

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed3.02 Unregistered Equity Sale5.02 Director / Officer Change5.03 Bylaw / Charter Amendment7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.